MediWound’s NexoBrid and EscharEx to be Featured at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MediWound’s NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016

YAVNE, Israel, Aug. 24, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company’s NexoBrid ® and EscharEx ® will be featured in multiple oral and poster presentations at the 18 th Congress of the International Society for Burn Injuries (ISBI) taking place August 29 - September 1, 2016 in Miami, Florida.  The presentation abstracts will be available online at www.isbi2016.com .

“We are delighted to once again have NexoBrid featured so prominently at this year’s ISBI, one of the world’s premier clinical meetings focused on the treatment and prevention of burns. The ISBI brings together the entire team of clinical professionals involved in caring for patients with severe burns in normal and mass casualties conditions on national and international levels,” stated Gal Cohen, President and Chief Executive Officer of MediWound.

“The presentations at ISBI highlight not only the success of NexoBrid in routine clinical use, but also in real life emergency situations such as the 2015 Romanian nightclub fire that resulted in a burn mass casualty incident, which is one of the featured oral presentations at the Congress,” added Mr. Cohen. “ISBI’s mission this year is to further elevate the standards-of-care in emerging countries where there are high burn incidence rates and more limited surgical capacity. We share their goals and look forward to the opportunity to communicate with leading burn specialists from Latin America, Asia-Pacific and other international regions in order to expand NexoBrid access to additional international markets where an effective non-surgical eschar removal agent can further improve burn care management and become the new standard-of-care for severe burns.”

The following abstracts regarding NexoBrid have been accepted for presentation by the ISBI organizing committee:

   
Paper Title:                         “ A Medical Training Program for the Introduction of NexoBrid Enzymatic Debridement to the Burn Community”
Date/Time: August 29th from 12:30 p.m. – 1:30 p.m.
Location: Exhibit Hall
   
Paper Title: “ Low Exposure Levels of Respirable Particles during the Preparation of NexoBrid® Bromelain Powder”
Date/Time: August 29th from 12:30 p.m. – 1:30 p.m.
Location: Exhibit Hall
   
Paper Title: “2015 Bucharest Night Club Fire”
Date/Time: August 29th from 1:30 p.m. – 3:00 p.m.
Location: Brickell
   
Paper Title: “Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement”
Date/Time: August 29 th from 3:30 p.m. – 5:00 p.m.
Location: Flagler
   
Paper Title: “The Use of Rapid Enzymatic Debridement in the 2015 Romanian Burn Mass Casualty Incident: Groundbreaking Experience”
Date/Time: August 29th from 3:30 p.m. – 5:00 p.m.
Location: Tuttle
   
Paper Title: “Rapid Enzymatic Debridement of Chronic Wounds: Results of a Multicenter Phase II Trial”
Date/Time: August 30th from 12:30 p.m. – 1:30 p.m.
Location: Exhibit Hall
   
Paper Title: “Early Debridement of Sulfur Mustard Contaminated Skin by NexoBrid: Results of a Concept Validation Pig Model Study”
Date/Time: August 30th from 3:30 p.m. – 5:00 p.m.
Location: Jasmine
   
Paper Title: “New Experience with NexoBrid in Milan Burn Centre: Pros and Cons”
Date/Time: August 30th at 3:30 p.m. – 5:00 p.m.
Location: Brickell
   
Paper Title: “Acute Healing and Early Scarring after Tissue Preserving Enzymatic Debridement of 13 Severely Burned Faces Compared to Traditional Surgical Debridement”
Date/Time: August 30th from 3:30 p.m. – 5:00 p.m.
Location: Monroe
   
Paper Title: “Introduction of NexoBrid for Wound Management: Lessons Learned after the First 25 Patients (1 year)”
Date/Time: August 30th from 3:30 p.m. – 5:00 p.m.
Location: Monroe
   
Paper Title: “The Role of Rapid Enzymatic Escharotomy and Escharectomy in Burn Mass Casualty Incidents”
Date/Time: August 31st at 12:30 p.m. – 1:30 p.m.
Location: Exhibit Hall
   
Paper Title: “Use of Enzymatic Debridement in Electrical Burn Injuries: A Case Report”
Date/Time: August 31st at 12:30 p.m. – 1:30 p.m.
Location: Exhibit Hall
   
Paper Title: “In Vivo Analysis of NexoBrid Enzymatic Debridement of Full Thickness Burns and Negative Pressure Wound Therapy”
Date/Time: August 31st at 12:30 p.m. – 1:30 p.m.
Location: Exhibit Hall
   
Paper Title: “The Treatment of Deep Partial Thickness Hand Burns after Enzymatic Debridement with NexoBrid: A Series of Case Reports”
Date/Time: September 1st at 10:30 a.m. – 12:00 p.m.
Location: Flagler
   

 

About the ISBI The International Society for Burn Injuries (ISBI) had its beginnings at the First International Congress on Research in Burns in Bethesda, Maryland in September 1960. Since the ISBI was founded, the total medical care of burn patients has improved considerably. This is not only because medical science has improved but also because there is also a better understanding of the need for a team of professionals of different specialties such as surgeons, anesthetists, bacteriologists, critical care physicians, nurses, dietitians, physiotherapists and others. Each and every one of these specialists plays a very important role.  One of the main purposes and aims of the ISBI is to disseminate knowledge and to stimulate prevention in the field of burns.

About NexoBrid

NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues.  NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe, Israel and Argentina. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid ® , received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe, Israel and Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue.

MediWound's second innovative product, EscharEx ® , is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx contains the same proteolytic enzyme technology as NexoBrid, and benefits from the wealth of existing development data on NexoBrid.  In two Phase 2 studies, EscharEx demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. 

For more information, please visit www.mediwound.com .  

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2015 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

 

           
Contacts:         Anne Marie Fields
Sharon Malka         Senior Vice President
Chief Financial and Operations Officer         LHA
MediWound         212-838-3777
ir@mediwound.co.il         afields@lhai.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 501

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 564

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 707

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 112

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 496

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading